1. Home
  2. INZY vs WILC Comparison

INZY vs WILC Comparison

Compare INZY & WILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INZY
  • WILC
  • Stock Information
  • Founded
  • INZY 2015
  • WILC 1994
  • Country
  • INZY United States
  • WILC Israel
  • Employees
  • INZY N/A
  • WILC N/A
  • Industry
  • INZY Biotechnology: Pharmaceutical Preparations
  • WILC Food Distributors
  • Sector
  • INZY Health Care
  • WILC Consumer Discretionary
  • Exchange
  • INZY Nasdaq
  • WILC Nasdaq
  • Market Cap
  • INZY 188.2M
  • WILC 225.9M
  • IPO Year
  • INZY 2020
  • WILC 1997
  • Fundamental
  • Price
  • INZY $1.36
  • WILC $15.79
  • Analyst Decision
  • INZY Strong Buy
  • WILC
  • Analyst Count
  • INZY 8
  • WILC 0
  • Target Price
  • INZY $17.75
  • WILC N/A
  • AVG Volume (30 Days)
  • INZY 784.0K
  • WILC 5.2K
  • Earning Date
  • INZY 03-11-2025
  • WILC 11-20-2024
  • Dividend Yield
  • INZY N/A
  • WILC 1.27%
  • EPS Growth
  • INZY N/A
  • WILC 69.67
  • EPS
  • INZY N/A
  • WILC 1.11
  • Revenue
  • INZY N/A
  • WILC $154,476,098.00
  • Revenue This Year
  • INZY N/A
  • WILC N/A
  • Revenue Next Year
  • INZY N/A
  • WILC N/A
  • P/E Ratio
  • INZY N/A
  • WILC $14.24
  • Revenue Growth
  • INZY N/A
  • WILC 6.79
  • 52 Week Low
  • INZY $1.32
  • WILC $8.18
  • 52 Week High
  • INZY $7.80
  • WILC $17.23
  • Technical
  • Relative Strength Index (RSI)
  • INZY 20.27
  • WILC 51.20
  • Support Level
  • INZY $1.32
  • WILC $15.40
  • Resistance Level
  • INZY $3.18
  • WILC $15.90
  • Average True Range (ATR)
  • INZY 0.27
  • WILC 0.40
  • MACD
  • INZY -0.15
  • WILC -0.17
  • Stochastic Oscillator
  • INZY 2.15
  • WILC 27.66

About INZY Inozyme Pharma Inc.

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

About WILC G. Willi-Food International Ltd.

G. Willi-Food International Ltd is a company engaged in the development, import, export, marketing, and distribution of a wide variety of over 650 food products worldwide. Its business segment includes import, export, marketing, and distribution of food products. The principal products in the import segment product line include Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.

Share on Social Networks: